MET and neoplasm: The patients were divided into four study arms, one with MET activating mutations in tumor tissue, one with MET activating mutations in circulating tumor DNA in the bloodstream, one with MET amplification in tumor tissue, and one with MET amplification in circulating tumor DNA.